Full history for every metric is available with a Kvantra account
Applied DNA Sciences, Inc. (APDN)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 9 | 18 | 13 | 3 | 2 | 2 |
| Operating profit | $m | -16 | -35 | |||||
| Net profit | $m | -13 | -16 | -8 | -10 | -7 | -69 | -66 |
| EPS reported | $ | -134.2 | -87.65 | |||||
| Operating cashflow per share | $ | -23.65 | -1.37 | |||||
| Capex per share | $ | 0.60 | 0.00 | |||||
| FCF per share | $ | -24.25 | -1.37 | |||||
| Free cash flow | $m | -13 | -11 | |||||
| Net debt | $m | -1 | -4 | |||||
| Book value equity | $m | 2 | 4 | |||||
| Book value per share | $ | 3.75 | 0.46 | |||||
| Number of shares | m | 0.52 | 8.37 | |||||
| DPS (TTM paid) | $ | 104.9 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.23 | 1.89 | |||||
| P/S LTM | x | 1.12 | 3.93 | |||||
| P/FCF LTM | x | -0.19 | -0.63 | |||||
| EV/EBITDA LTM | x | 2.40 | 0.50 | |||||
| EV/Sales LTM | x | 0.43 | 1.89 | |||||
| Earnings Yield LTM | % | -2899.2% | -139.80% | |||||
| FCF Yield | % | -523.85% | -158.36% | |||||
| Quality | ||||||||
| ROE | % | -3578.7% | -722.67% | |||||
| ROIC | % | -740.57% | -246.94% | |||||
| Operating margin | % | -750.92% | -1874.4% | |||||
| Gross margin | % | 39.26% | 74.06% | |||||
| FCF/Sales | % | -587.56% | -622.13% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -37.72% | -43.98% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 2266.6% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -78.18% | -2.58% | |||||
| FCF/Debt | x | -64.97 | - | |||||
| Net Debt/EBITDA | x | -3.84 | -0.54 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -61.52% | -51.83% | |||||
| Net debt/Equity | x | -0.76 | -0.98 | |||||
| Gross debt/equity | x | 0.10 | 0.00 | |||||
Company overview
Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Applied DNA Sciences, Inc. (APDN)
Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free